Disorders of MicroRNAs in peripheral blood mononuclear cells: As novel biomarkers of ankylosing spondylitis and provocative therapeutic targets

29Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Background. MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders. Result. The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept therapy than in control group. Marched fold changes of them were 3.76 and 16.22. Moreover, expressions of hsa-miR-126-3p and hsa-miR-29a were dramatically upregulated after 12-weeks etanercept treatment. Fold changes were 2.20 and 3.18. All regulations of microRNAs expression mentioned before were statistically significant (fold change >2 and P < 0.05). The expression disorders of the 2 microRNAs did not statistically significantly correlated with BASDAI, CRP, and ESR. Conclusion. AS pathogenesis involved dysregulation of microRNAs. Hsa-miR-126-3p and hsa-miR-29a will probably become the potential biomarkers and provocative therapeutic targets of AS.

Cite

CITATION STYLE

APA

Lv, Q., Li, Q., Zhang, P., Jiang, Y., Wang, X., Wei, Q., … Gu, J. (2015). Disorders of MicroRNAs in peripheral blood mononuclear cells: As novel biomarkers of ankylosing spondylitis and provocative therapeutic targets. BioMed Research International, 2015. https://doi.org/10.1155/2015/504208

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free